Hollie Adams/Brendan McDermid/ReutersA new anti-obesity pill appears to be as effective as Ozempic in reducing weight, a trial suggested. GLP-1 weight loss drugs are enormously popular: Semaglutide, better known as Ozempic or Wegovy, is the second-biggest selling drug in the world, making its manufacturer Europe’s most valuable firm. But they require injecting, which makes them inconvenient and unpleasant for some patients; an oral form of semaglutide is available but less effective. Eli Lilly, which makes Ozempic’s key rival Zepbound, is developing an ingestible drug, orforglipron. Phase III trial data found that patients lost on average 7.9% of their body weight in the trial period, comparable to existing drugs, and it was also effective in lowering blood sugar in diabetics. |